nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclophosphamide—CYP2B6—Thiotepa—sarcoma	0.151	0.246	CbGbCtD
Cyclophosphamide—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0469	0.0763	CbGbCtD
Cyclophosphamide—CYP3A7—Vincristine—sarcoma	0.0469	0.0763	CbGbCtD
Cyclophosphamide—CYP3A4—Thiotepa—sarcoma	0.0464	0.0755	CbGbCtD
Cyclophosphamide—ABCB1—Dactinomycin—sarcoma	0.0372	0.0605	CbGbCtD
Cyclophosphamide—CYP3A5—Vincristine—sarcoma	0.0352	0.0573	CbGbCtD
Cyclophosphamide—ABCB1—Mitoxantrone—sarcoma	0.0333	0.0542	CbGbCtD
Cyclophosphamide—CYP3A5—Etoposide—sarcoma	0.0323	0.0525	CbGbCtD
Cyclophosphamide—CYP2C8—Etoposide—sarcoma	0.031	0.0505	CbGbCtD
Cyclophosphamide—CYP2B6—Doxorubicin—sarcoma	0.0279	0.0454	CbGbCtD
Cyclophosphamide—ABCB1—Vincristine—sarcoma	0.0229	0.0373	CbGbCtD
Cyclophosphamide—ABCB1—Etoposide—sarcoma	0.021	0.0342	CbGbCtD
Cyclophosphamide—CYP3A4—Mitoxantrone—sarcoma	0.02	0.0324	CbGbCtD
Cyclophosphamide—ABCB1—Doxorubicin—sarcoma	0.0143	0.0233	CbGbCtD
Cyclophosphamide—CYP3A4—Vincristine—sarcoma	0.0137	0.0223	CbGbCtD
Cyclophosphamide—CYP2D6—Doxorubicin—sarcoma	0.0135	0.0219	CbGbCtD
Cyclophosphamide—CYP3A4—Etoposide—sarcoma	0.0126	0.0205	CbGbCtD
Cyclophosphamide—CYP3A4—Doxorubicin—sarcoma	0.00858	0.014	CbGbCtD
Cyclophosphamide—Feeling abnormal—Dactinomycin—sarcoma	0.000175	0.000455	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Etoposide—sarcoma	0.000175	0.000454	CcSEcCtD
Cyclophosphamide—Anaemia—Etoposide—sarcoma	0.000174	0.000452	CcSEcCtD
Cyclophosphamide—Hot flush—Doxorubicin—sarcoma	0.000174	0.000451	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Vincristine—sarcoma	0.000173	0.000449	CcSEcCtD
Cyclophosphamide—Hypotension—Mitoxantrone—sarcoma	0.000173	0.000449	CcSEcCtD
Cyclophosphamide—Menopausal symptoms—Doxorubicin—sarcoma	0.000172	0.000447	CcSEcCtD
Cyclophosphamide—Renal impairment—Doxorubicin—sarcoma	0.000171	0.000443	CcSEcCtD
Cyclophosphamide—Paraesthesia—Vincristine—sarcoma	0.000171	0.000443	CcSEcCtD
Cyclophosphamide—Urticaria—Thiotepa—sarcoma	0.00017	0.000442	CcSEcCtD
Cyclophosphamide—Malaise—Etoposide—sarcoma	0.00017	0.000441	CcSEcCtD
Cyclophosphamide—Dermatitis bullous—Doxorubicin—sarcoma	0.00017	0.000441	CcSEcCtD
Cyclophosphamide—Body temperature increased—Thiotepa—sarcoma	0.000169	0.00044	CcSEcCtD
Cyclophosphamide—Leukopenia—Etoposide—sarcoma	0.000169	0.000438	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000168	0.000438	CcSEcCtD
Cyclophosphamide—Body temperature increased—Dactinomycin—sarcoma	0.000168	0.000436	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Epirubicin—sarcoma	0.000167	0.000433	CcSEcCtD
Cyclophosphamide—Cardiac failure—Doxorubicin—sarcoma	0.000166	0.000432	CcSEcCtD
Cyclophosphamide—Paraesthesia—Mitoxantrone—sarcoma	0.000166	0.000431	CcSEcCtD
Cyclophosphamide—Decreased appetite—Vincristine—sarcoma	0.000165	0.000429	CcSEcCtD
Cyclophosphamide—Dyspnoea—Mitoxantrone—sarcoma	0.000165	0.000428	CcSEcCtD
Cyclophosphamide—Cough—Etoposide—sarcoma	0.000164	0.000427	CcSEcCtD
Cyclophosphamide—Fatigue—Vincristine—sarcoma	0.000164	0.000425	CcSEcCtD
Cyclophosphamide—Convulsion—Etoposide—sarcoma	0.000163	0.000424	CcSEcCtD
Cyclophosphamide—Hyponatraemia—Doxorubicin—sarcoma	0.000163	0.000423	CcSEcCtD
Cyclophosphamide—Hypertension—Etoposide—sarcoma	0.000163	0.000423	CcSEcCtD
Cyclophosphamide—Pain—Vincristine—sarcoma	0.000162	0.000422	CcSEcCtD
Cyclophosphamide—Constipation—Vincristine—sarcoma	0.000162	0.000422	CcSEcCtD
Cyclophosphamide—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.000162	0.000422	CcSEcCtD
Cyclophosphamide—Decreased appetite—Mitoxantrone—sarcoma	0.000161	0.000417	CcSEcCtD
Cyclophosphamide—Chest pain—Etoposide—sarcoma	0.00016	0.000417	CcSEcCtD
Cyclophosphamide—Fatigue—Mitoxantrone—sarcoma	0.000159	0.000414	CcSEcCtD
Cyclophosphamide—Discomfort—Etoposide—sarcoma	0.000159	0.000412	CcSEcCtD
Cyclophosphamide—Pain—Mitoxantrone—sarcoma	0.000158	0.000411	CcSEcCtD
Cyclophosphamide—Constipation—Mitoxantrone—sarcoma	0.000158	0.000411	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000158	0.00041	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Thiotepa—sarcoma	0.000158	0.00041	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Epirubicin—sarcoma	0.000157	0.000407	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Dactinomycin—sarcoma	0.000157	0.000407	CcSEcCtD
Cyclophosphamide—Confusional state—Etoposide—sarcoma	0.000155	0.000403	CcSEcCtD
Cyclophosphamide—Cardiac arrest—Doxorubicin—sarcoma	0.000154	0.000401	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Etoposide—sarcoma	0.000154	0.000399	CcSEcCtD
Cyclophosphamide—Asthenia—Thiotepa—sarcoma	0.000154	0.000399	CcSEcCtD
Cyclophosphamide—Infection—Etoposide—sarcoma	0.000153	0.000397	CcSEcCtD
Cyclophosphamide—Asthenia—Dactinomycin—sarcoma	0.000152	0.000396	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Mitoxantrone—sarcoma	0.000152	0.000396	CcSEcCtD
Cyclophosphamide—Pruritus—Thiotepa—sarcoma	0.000152	0.000393	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Etoposide—sarcoma	0.000151	0.000391	CcSEcCtD
Cyclophosphamide—Tachycardia—Etoposide—sarcoma	0.00015	0.00039	CcSEcCtD
Cyclophosphamide—Body temperature increased—Vincristine—sarcoma	0.00015	0.00039	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Etoposide—sarcoma	0.000149	0.000386	CcSEcCtD
Cyclophosphamide—Urticaria—Mitoxantrone—sarcoma	0.000147	0.000381	CcSEcCtD
Cyclophosphamide—Anorexia—Etoposide—sarcoma	0.000147	0.000381	CcSEcCtD
Cyclophosphamide—Diarrhoea—Thiotepa—sarcoma	0.000147	0.00038	CcSEcCtD
Cyclophosphamide—Body temperature increased—Mitoxantrone—sarcoma	0.000146	0.00038	CcSEcCtD
Cyclophosphamide—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000146	0.00038	CcSEcCtD
Cyclophosphamide—Diarrhoea—Dactinomycin—sarcoma	0.000145	0.000378	CcSEcCtD
Cyclophosphamide—Nasopharyngitis—Doxorubicin—sarcoma	0.000145	0.000377	CcSEcCtD
Cyclophosphamide—Pancytopenia—Epirubicin—sarcoma	0.000144	0.000374	CcSEcCtD
Cyclophosphamide—Hypotension—Etoposide—sarcoma	0.000144	0.000373	CcSEcCtD
Cyclophosphamide—Dizziness—Thiotepa—sarcoma	0.000142	0.000368	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Vincristine—sarcoma	0.00014	0.000363	CcSEcCtD
Cyclophosphamide—Paraesthesia—Etoposide—sarcoma	0.000138	0.000359	CcSEcCtD
Cyclophosphamide—Weight increased—Epirubicin—sarcoma	0.000138	0.000358	CcSEcCtD
Cyclophosphamide—Dyspnoea—Etoposide—sarcoma	0.000137	0.000356	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Epirubicin—sarcoma	0.000137	0.000355	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Mitoxantrone—sarcoma	0.000136	0.000354	CcSEcCtD
Cyclophosphamide—Asthenia—Vincristine—sarcoma	0.000136	0.000354	CcSEcCtD
Cyclophosphamide—Vomiting—Thiotepa—sarcoma	0.000136	0.000354	CcSEcCtD
Cyclophosphamide—Pneumonia—Epirubicin—sarcoma	0.000136	0.000353	CcSEcCtD
Cyclophosphamide—Vomiting—Dactinomycin—sarcoma	0.000135	0.000351	CcSEcCtD
Cyclophosphamide—Rash—Thiotepa—sarcoma	0.000135	0.000351	CcSEcCtD
Cyclophosphamide—Dermatitis—Thiotepa—sarcoma	0.000135	0.00035	CcSEcCtD
Cyclophosphamide—Headache—Thiotepa—sarcoma	0.000134	0.000348	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000134	0.000348	CcSEcCtD
Cyclophosphamide—Rash—Dactinomycin—sarcoma	0.000134	0.000348	CcSEcCtD
Cyclophosphamide—Decreased appetite—Etoposide—sarcoma	0.000134	0.000347	CcSEcCtD
Cyclophosphamide—Pancytopenia—Doxorubicin—sarcoma	0.000133	0.000346	CcSEcCtD
Cyclophosphamide—Renal failure—Epirubicin—sarcoma	0.000133	0.000345	CcSEcCtD
Cyclophosphamide—Asthenia—Mitoxantrone—sarcoma	0.000133	0.000345	CcSEcCtD
Cyclophosphamide—Fatigue—Etoposide—sarcoma	0.000133	0.000344	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Epirubicin—sarcoma	0.000133	0.000344	CcSEcCtD
Cyclophosphamide—Stomatitis—Epirubicin—sarcoma	0.000132	0.000342	CcSEcCtD
Cyclophosphamide—Jaundice—Epirubicin—sarcoma	0.000132	0.000342	CcSEcCtD
Cyclophosphamide—Pain—Etoposide—sarcoma	0.000132	0.000342	CcSEcCtD
Cyclophosphamide—Constipation—Etoposide—sarcoma	0.000132	0.000342	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Epirubicin—sarcoma	0.000131	0.000341	CcSEcCtD
Cyclophosphamide—Diarrhoea—Vincristine—sarcoma	0.00013	0.000337	CcSEcCtD
Cyclophosphamide—Sweating—Epirubicin—sarcoma	0.00013	0.000337	CcSEcCtD
Cyclophosphamide—Haematuria—Epirubicin—sarcoma	0.000129	0.000335	CcSEcCtD
Cyclophosphamide—Weight increased—Doxorubicin—sarcoma	0.000128	0.000332	CcSEcCtD
Cyclophosphamide—Nausea—Thiotepa—sarcoma	0.000127	0.00033	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Etoposide—sarcoma	0.000127	0.000329	CcSEcCtD
Cyclophosphamide—Hyperglycaemia—Doxorubicin—sarcoma	0.000127	0.000329	CcSEcCtD
Cyclophosphamide—Diarrhoea—Mitoxantrone—sarcoma	0.000127	0.000329	CcSEcCtD
Cyclophosphamide—Nausea—Dactinomycin—sarcoma	0.000126	0.000328	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Epirubicin—sarcoma	0.000126	0.000328	CcSEcCtD
Cyclophosphamide—Pneumonia—Doxorubicin—sarcoma	0.000126	0.000327	CcSEcCtD
Cyclophosphamide—Dizziness—Vincristine—sarcoma	0.000126	0.000326	CcSEcCtD
Cyclophosphamide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000124	0.000322	CcSEcCtD
Cyclophosphamide—Bradycardia—Epirubicin—sarcoma	0.000124	0.000321	CcSEcCtD
Cyclophosphamide—Renal failure—Doxorubicin—sarcoma	0.000123	0.000319	CcSEcCtD
Cyclophosphamide—Neuropathy peripheral—Doxorubicin—sarcoma	0.000123	0.000318	CcSEcCtD
Cyclophosphamide—Urticaria—Etoposide—sarcoma	0.000122	0.000317	CcSEcCtD
Cyclophosphamide—Haemoglobin—Epirubicin—sarcoma	0.000122	0.000317	CcSEcCtD
Cyclophosphamide—Stomatitis—Doxorubicin—sarcoma	0.000122	0.000317	CcSEcCtD
Cyclophosphamide—Jaundice—Doxorubicin—sarcoma	0.000122	0.000317	CcSEcCtD
Cyclophosphamide—Rhinitis—Epirubicin—sarcoma	0.000122	0.000316	CcSEcCtD
Cyclophosphamide—Body temperature increased—Etoposide—sarcoma	0.000122	0.000316	CcSEcCtD
Cyclophosphamide—Conjunctivitis—Doxorubicin—sarcoma	0.000122	0.000316	CcSEcCtD
Cyclophosphamide—Haemorrhage—Epirubicin—sarcoma	0.000121	0.000315	CcSEcCtD
Cyclophosphamide—Hepatitis—Epirubicin—sarcoma	0.000121	0.000315	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Epirubicin—sarcoma	0.000121	0.000314	CcSEcCtD
Cyclophosphamide—Vomiting—Vincristine—sarcoma	0.000121	0.000314	CcSEcCtD
Cyclophosphamide—Sweating—Doxorubicin—sarcoma	0.00012	0.000311	CcSEcCtD
Cyclophosphamide—Rash—Vincristine—sarcoma	0.00012	0.000311	CcSEcCtD
Cyclophosphamide—Dermatitis—Vincristine—sarcoma	0.00012	0.000311	CcSEcCtD
Cyclophosphamide—Haematuria—Doxorubicin—sarcoma	0.000119	0.00031	CcSEcCtD
Cyclophosphamide—Headache—Vincristine—sarcoma	0.000119	0.000309	CcSEcCtD
Cyclophosphamide—Vomiting—Mitoxantrone—sarcoma	0.000118	0.000305	CcSEcCtD
Cyclophosphamide—Visual impairment—Epirubicin—sarcoma	0.000117	0.000304	CcSEcCtD
Cyclophosphamide—Agranulocytosis—Doxorubicin—sarcoma	0.000117	0.000303	CcSEcCtD
Cyclophosphamide—Rash—Mitoxantrone—sarcoma	0.000117	0.000303	CcSEcCtD
Cyclophosphamide—Dermatitis—Mitoxantrone—sarcoma	0.000116	0.000303	CcSEcCtD
Cyclophosphamide—Headache—Mitoxantrone—sarcoma	0.000116	0.000301	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Epirubicin—sarcoma	0.000115	0.000298	CcSEcCtD
Cyclophosphamide—Bradycardia—Doxorubicin—sarcoma	0.000114	0.000297	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Etoposide—sarcoma	0.000113	0.000294	CcSEcCtD
Cyclophosphamide—Tinnitus—Epirubicin—sarcoma	0.000113	0.000294	CcSEcCtD
Cyclophosphamide—Haemoglobin—Doxorubicin—sarcoma	0.000113	0.000293	CcSEcCtD
Cyclophosphamide—Nausea—Vincristine—sarcoma	0.000113	0.000293	CcSEcCtD
Cyclophosphamide—Flushing—Epirubicin—sarcoma	0.000113	0.000292	CcSEcCtD
Cyclophosphamide—Rhinitis—Doxorubicin—sarcoma	0.000113	0.000292	CcSEcCtD
Cyclophosphamide—Haemorrhage—Doxorubicin—sarcoma	0.000112	0.000292	CcSEcCtD
Cyclophosphamide—Hepatitis—Doxorubicin—sarcoma	0.000112	0.000292	CcSEcCtD
Cyclophosphamide—Hypoaesthesia—Doxorubicin—sarcoma	0.000112	0.00029	CcSEcCtD
Cyclophosphamide—Asthenia—Etoposide—sarcoma	0.00011	0.000287	CcSEcCtD
Cyclophosphamide—Nausea—Mitoxantrone—sarcoma	0.00011	0.000285	CcSEcCtD
Cyclophosphamide—Chills—Epirubicin—sarcoma	0.000109	0.000283	CcSEcCtD
Cyclophosphamide—Pruritus—Etoposide—sarcoma	0.000109	0.000283	CcSEcCtD
Cyclophosphamide—Arrhythmia—Epirubicin—sarcoma	0.000108	0.000282	CcSEcCtD
Cyclophosphamide—Visual impairment—Doxorubicin—sarcoma	0.000108	0.000281	CcSEcCtD
Cyclophosphamide—Alopecia—Epirubicin—sarcoma	0.000107	0.000278	CcSEcCtD
Cyclophosphamide—Erythema multiforme—Doxorubicin—sarcoma	0.000106	0.000276	CcSEcCtD
Cyclophosphamide—Erythema—Epirubicin—sarcoma	0.000106	0.000274	CcSEcCtD
Cyclophosphamide—Diarrhoea—Etoposide—sarcoma	0.000105	0.000273	CcSEcCtD
Cyclophosphamide—Tinnitus—Doxorubicin—sarcoma	0.000105	0.000272	CcSEcCtD
Cyclophosphamide—Flushing—Doxorubicin—sarcoma	0.000104	0.000271	CcSEcCtD
Cyclophosphamide—Dysgeusia—Epirubicin—sarcoma	0.000103	0.000269	CcSEcCtD
Cyclophosphamide—Dizziness—Etoposide—sarcoma	0.000102	0.000264	CcSEcCtD
Cyclophosphamide—Muscle spasms—Epirubicin—sarcoma	0.000102	0.000264	CcSEcCtD
Cyclophosphamide—Chills—Doxorubicin—sarcoma	0.000101	0.000262	CcSEcCtD
Cyclophosphamide—Arrhythmia—Doxorubicin—sarcoma	0.0001	0.000261	CcSEcCtD
Cyclophosphamide—Vision blurred—Epirubicin—sarcoma	9.96e-05	0.000259	CcSEcCtD
Cyclophosphamide—Alopecia—Doxorubicin—sarcoma	9.92e-05	0.000258	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Epirubicin—sarcoma	9.8e-05	0.000255	CcSEcCtD
Cyclophosphamide—Vomiting—Etoposide—sarcoma	9.78e-05	0.000254	CcSEcCtD
Cyclophosphamide—Erythema—Doxorubicin—sarcoma	9.78e-05	0.000254	CcSEcCtD
Cyclophosphamide—Anaemia—Epirubicin—sarcoma	9.76e-05	0.000254	CcSEcCtD
Cyclophosphamide—Agitation—Epirubicin—sarcoma	9.71e-05	0.000252	CcSEcCtD
Cyclophosphamide—Rash—Etoposide—sarcoma	9.7e-05	0.000252	CcSEcCtD
Cyclophosphamide—Dermatitis—Etoposide—sarcoma	9.69e-05	0.000252	CcSEcCtD
Cyclophosphamide—Headache—Etoposide—sarcoma	9.64e-05	0.00025	CcSEcCtD
Cyclophosphamide—Dysgeusia—Doxorubicin—sarcoma	9.57e-05	0.000249	CcSEcCtD
Cyclophosphamide—Malaise—Epirubicin—sarcoma	9.53e-05	0.000247	CcSEcCtD
Cyclophosphamide—Leukopenia—Epirubicin—sarcoma	9.46e-05	0.000246	CcSEcCtD
Cyclophosphamide—Muscle spasms—Doxorubicin—sarcoma	9.4e-05	0.000244	CcSEcCtD
Cyclophosphamide—Palpitations—Epirubicin—sarcoma	9.34e-05	0.000242	CcSEcCtD
Cyclophosphamide—Cough—Epirubicin—sarcoma	9.22e-05	0.000239	CcSEcCtD
Cyclophosphamide—Vision blurred—Doxorubicin—sarcoma	9.21e-05	0.000239	CcSEcCtD
Cyclophosphamide—Convulsion—Epirubicin—sarcoma	9.15e-05	0.000238	CcSEcCtD
Cyclophosphamide—Nausea—Etoposide—sarcoma	9.14e-05	0.000237	CcSEcCtD
Cyclophosphamide—Hypertension—Epirubicin—sarcoma	9.12e-05	0.000237	CcSEcCtD
Cyclophosphamide—Ill-defined disorder—Doxorubicin—sarcoma	9.07e-05	0.000236	CcSEcCtD
Cyclophosphamide—Anaemia—Doxorubicin—sarcoma	9.04e-05	0.000235	CcSEcCtD
Cyclophosphamide—Chest pain—Epirubicin—sarcoma	8.99e-05	0.000234	CcSEcCtD
Cyclophosphamide—Arthralgia—Epirubicin—sarcoma	8.99e-05	0.000234	CcSEcCtD
Cyclophosphamide—Myalgia—Epirubicin—sarcoma	8.99e-05	0.000234	CcSEcCtD
Cyclophosphamide—Agitation—Doxorubicin—sarcoma	8.98e-05	0.000233	CcSEcCtD
Cyclophosphamide—Discomfort—Epirubicin—sarcoma	8.89e-05	0.000231	CcSEcCtD
Cyclophosphamide—Malaise—Doxorubicin—sarcoma	8.82e-05	0.000229	CcSEcCtD
Cyclophosphamide—Leukopenia—Doxorubicin—sarcoma	8.75e-05	0.000227	CcSEcCtD
Cyclophosphamide—Confusional state—Epirubicin—sarcoma	8.69e-05	0.000226	CcSEcCtD
Cyclophosphamide—Palpitations—Doxorubicin—sarcoma	8.64e-05	0.000224	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Epirubicin—sarcoma	8.62e-05	0.000224	CcSEcCtD
Cyclophosphamide—Oedema—Epirubicin—sarcoma	8.62e-05	0.000224	CcSEcCtD
Cyclophosphamide—Infection—Epirubicin—sarcoma	8.57e-05	0.000222	CcSEcCtD
Cyclophosphamide—Cough—Doxorubicin—sarcoma	8.53e-05	0.000222	CcSEcCtD
Cyclophosphamide—Shock—Epirubicin—sarcoma	8.48e-05	0.00022	CcSEcCtD
Cyclophosphamide—Convulsion—Doxorubicin—sarcoma	8.47e-05	0.00022	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Epirubicin—sarcoma	8.44e-05	0.000219	CcSEcCtD
Cyclophosphamide—Hypertension—Doxorubicin—sarcoma	8.44e-05	0.000219	CcSEcCtD
Cyclophosphamide—Tachycardia—Epirubicin—sarcoma	8.42e-05	0.000219	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Epirubicin—sarcoma	8.34e-05	0.000216	CcSEcCtD
Cyclophosphamide—Myalgia—Doxorubicin—sarcoma	8.32e-05	0.000216	CcSEcCtD
Cyclophosphamide—Arthralgia—Doxorubicin—sarcoma	8.32e-05	0.000216	CcSEcCtD
Cyclophosphamide—Chest pain—Doxorubicin—sarcoma	8.32e-05	0.000216	CcSEcCtD
Cyclophosphamide—Discomfort—Doxorubicin—sarcoma	8.22e-05	0.000214	CcSEcCtD
Cyclophosphamide—Anorexia—Epirubicin—sarcoma	8.22e-05	0.000213	CcSEcCtD
Cyclophosphamide—Hypotension—Epirubicin—sarcoma	8.06e-05	0.000209	CcSEcCtD
Cyclophosphamide—Confusional state—Doxorubicin—sarcoma	8.04e-05	0.000209	CcSEcCtD
Cyclophosphamide—Anaphylactic shock—Doxorubicin—sarcoma	7.98e-05	0.000207	CcSEcCtD
Cyclophosphamide—Oedema—Doxorubicin—sarcoma	7.98e-05	0.000207	CcSEcCtD
Cyclophosphamide—Infection—Doxorubicin—sarcoma	7.93e-05	0.000206	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Epirubicin—sarcoma	7.86e-05	0.000204	CcSEcCtD
Cyclophosphamide—Shock—Doxorubicin—sarcoma	7.85e-05	0.000204	CcSEcCtD
Cyclophosphamide—Thrombocytopenia—Doxorubicin—sarcoma	7.81e-05	0.000203	CcSEcCtD
Cyclophosphamide—Tachycardia—Doxorubicin—sarcoma	7.79e-05	0.000202	CcSEcCtD
Cyclophosphamide—Paraesthesia—Epirubicin—sarcoma	7.74e-05	0.000201	CcSEcCtD
Cyclophosphamide—Hyperhidrosis—Doxorubicin—sarcoma	7.71e-05	0.0002	CcSEcCtD
Cyclophosphamide—Dyspnoea—Epirubicin—sarcoma	7.69e-05	0.0002	CcSEcCtD
Cyclophosphamide—Anorexia—Doxorubicin—sarcoma	7.6e-05	0.000197	CcSEcCtD
Cyclophosphamide—Decreased appetite—Epirubicin—sarcoma	7.5e-05	0.000195	CcSEcCtD
Cyclophosphamide—Hypotension—Doxorubicin—sarcoma	7.45e-05	0.000194	CcSEcCtD
Cyclophosphamide—Fatigue—Epirubicin—sarcoma	7.43e-05	0.000193	CcSEcCtD
Cyclophosphamide—Pain—Epirubicin—sarcoma	7.37e-05	0.000191	CcSEcCtD
Cyclophosphamide—Constipation—Epirubicin—sarcoma	7.37e-05	0.000191	CcSEcCtD
Cyclophosphamide—Musculoskeletal discomfort—Doxorubicin—sarcoma	7.27e-05	0.000189	CcSEcCtD
Cyclophosphamide—Paraesthesia—Doxorubicin—sarcoma	7.16e-05	0.000186	CcSEcCtD
Cyclophosphamide—Dyspnoea—Doxorubicin—sarcoma	7.11e-05	0.000185	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Epirubicin—sarcoma	7.11e-05	0.000185	CcSEcCtD
Cyclophosphamide—Decreased appetite—Doxorubicin—sarcoma	6.94e-05	0.00018	CcSEcCtD
Cyclophosphamide—Fatigue—Doxorubicin—sarcoma	6.88e-05	0.000179	CcSEcCtD
Cyclophosphamide—Urticaria—Epirubicin—sarcoma	6.85e-05	0.000178	CcSEcCtD
Cyclophosphamide—Pain—Doxorubicin—sarcoma	6.82e-05	0.000177	CcSEcCtD
Cyclophosphamide—Constipation—Doxorubicin—sarcoma	6.82e-05	0.000177	CcSEcCtD
Cyclophosphamide—Body temperature increased—Epirubicin—sarcoma	6.82e-05	0.000177	CcSEcCtD
Cyclophosphamide—Feeling abnormal—Doxorubicin—sarcoma	6.57e-05	0.000171	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Epirubicin—sarcoma	6.35e-05	0.000165	CcSEcCtD
Cyclophosphamide—Urticaria—Doxorubicin—sarcoma	6.34e-05	0.000165	CcSEcCtD
Cyclophosphamide—Body temperature increased—Doxorubicin—sarcoma	6.31e-05	0.000164	CcSEcCtD
Cyclophosphamide—Asthenia—Epirubicin—sarcoma	6.19e-05	0.000161	CcSEcCtD
Cyclophosphamide—Pruritus—Epirubicin—sarcoma	6.1e-05	0.000158	CcSEcCtD
Cyclophosphamide—Diarrhoea—Epirubicin—sarcoma	5.9e-05	0.000153	CcSEcCtD
Cyclophosphamide—Hypersensitivity—Doxorubicin—sarcoma	5.88e-05	0.000153	CcSEcCtD
Cyclophosphamide—Asthenia—Doxorubicin—sarcoma	5.72e-05	0.000149	CcSEcCtD
Cyclophosphamide—Dizziness—Epirubicin—sarcoma	5.7e-05	0.000148	CcSEcCtD
Cyclophosphamide—Pruritus—Doxorubicin—sarcoma	5.64e-05	0.000147	CcSEcCtD
Cyclophosphamide—Vomiting—Epirubicin—sarcoma	5.48e-05	0.000142	CcSEcCtD
Cyclophosphamide—Diarrhoea—Doxorubicin—sarcoma	5.46e-05	0.000142	CcSEcCtD
Cyclophosphamide—Rash—Epirubicin—sarcoma	5.44e-05	0.000141	CcSEcCtD
Cyclophosphamide—Dermatitis—Epirubicin—sarcoma	5.43e-05	0.000141	CcSEcCtD
Cyclophosphamide—Headache—Epirubicin—sarcoma	5.4e-05	0.00014	CcSEcCtD
Cyclophosphamide—Dizziness—Doxorubicin—sarcoma	5.28e-05	0.000137	CcSEcCtD
Cyclophosphamide—Nausea—Epirubicin—sarcoma	5.12e-05	0.000133	CcSEcCtD
Cyclophosphamide—Vomiting—Doxorubicin—sarcoma	5.07e-05	0.000132	CcSEcCtD
Cyclophosphamide—Rash—Doxorubicin—sarcoma	5.03e-05	0.000131	CcSEcCtD
Cyclophosphamide—Dermatitis—Doxorubicin—sarcoma	5.03e-05	0.000131	CcSEcCtD
Cyclophosphamide—Headache—Doxorubicin—sarcoma	5e-05	0.00013	CcSEcCtD
Cyclophosphamide—Nausea—Doxorubicin—sarcoma	4.74e-05	0.000123	CcSEcCtD
